Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domatinostat + Avelumab in Advanced Merkel Cell Carcinoma
NCT04393753Phase 2Completed
- Sponsor
- 4SC AG
- Start
- Oct 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of Domatinostat in Merkel cell carcinoma (MCC), sponsored by 4SC AG. Primary endpoint: Objective Response Rate at 24 months. Started Oct 2020; status: completed.
02
Drugs
Domatinostat
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04393753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393753.